New Delhi, Feb. 2 -- The union Budget 2026-27 has signalled a decisive policy shift by placing biopharmaceuticals at the core of India's healthcare and manufacturing strategy.
With the announcement of the Biopharma SHAKTI initiative, backed by an outlay of Rs 10,000 crore over five years, the government aims to transform India into a leading global hub for biologics and biosimilars and secure 5 per cent of the global biopharmaceutical market.
The Budget acknowledges the growing burden of non-communicable diseases such as cancer, diabetes, and autoimmune disorders, alongside the increasing global reliance on biologic medicines.
By prioritising biopharma, the government is seeking to move India up the pharmaceutical value chain from being ...